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The tremendous successes of mammalian cell culture engineering since the 1980’s made our modern era of 
protein therapeutics a reality, bringing tremendous new possibilities for targeted intervention, but also additional 
challenges in pre-clinical development due to the species specificity of biologics. While the efficacy and safety of 
all drugs intended for humans is often difficult to extrapolate from assays in animal models and traditional cell 
cultures, the situation is significantly more difficult for biologics. Traditional cell culture modes, even with human 
cells, often fail to capture the complexity of pathways, which may involve multiple cell types and cross-talk 
between different organ systems.  The species specificity of most biologics precludes testing in most common 
animal models. Thus, adverse events are observed in the clinic due to lack of adequate predictive models.  For 
example, the anti IL-6 receptor Tocilizumab, developed to treat chronic inflammatory diseases like arthritis, 
earned a warning label from the FDA after clinical evidence that the metabolism of statins and other drugs was 
altered by Tocilizumab in ways that were not predicted by pre-clinical models. (Long, Cosgrove et al. 2016). 
 
The modern field of “organs-on-chips” or “microphysiological systems (MPS)” is poised to address these gaps, 
and is coming full circle back to the wealth of knowledge about cell culture bioreactor performance produced by 
the therapeutic protein field.  The field of “organs on chips” had its origins several decades ago with 
demonstrations by Michael Shuler and others that facets of human drug pharmacokinetics could be replicated 
by interconnected cultures of various cell lines (liver, fat, etc).  These initial demonstrations were powerful but 
ultimately limited by the simplicity of the cell cultures – cell lines that mimicked only modest facets of the 
functions of the in vivo organ system.  Over the past decades, tremendous advances in microfluidics, 
biomaterials, and technologies to process and make available primary human cells have dramatically increased 
the human-ness of in vitro cultures. Interestingly, cell lines are also still commonly used, and there has not yet 
been a thoughtful appreciation of how the basic metabolic functions of the tissue engineered constructs may 
affect the performance of these systems.  Special challenges exist in formulating common media, for example, 
in interconnected organ systems where some cells are primary, some are tumor-derived lines, and yet others 
are from iPS-derived sources. 
 
In this talk, I will highlight the past, present and future interplay between these two dynamic, vibrant fields, with 
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